We identified a novel and potential therapeutic strategy by co-targeting BET bromodomain BRD4 and RAC1 signaling pathways in different molecular subtypes of breast cancer including luminal-A, TNBC and HER-2 positive breast cancer. The gene discussed is ERBB2; the disease is breast cancer.